The Real-World Cost-Effectiveness of Coronary Artery Bypass Surgery Versus Stenting in High-Risk Patients: Propensity Score-Matched Analysis of a Single-Centre Experience
- 86 Downloads
There are limited economic evaluations comparing coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI) for multi-vessel coronary artery disease (MVCAD) in contemporary, routine clinical practice.
The aim was to perform a cost-effectiveness analysis comparing CABG and PCI in patients with MVCAD, from the perspective of the Australian public hospital payer, using observational data sources.
Clinical data from the Melbourne Interventional Group (MIG) and the Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) registries were analysed for 1022 CABG (treatment) and 978 PCI (comparator) procedures performed between June 2009 and December 2013. Clinical records were linked to same-hospital admissions and national death index (NDI) data. The incremental cost-effectiveness ratios (ICERs) per major adverse cardiac and cerebrovascular event (MACCE) avoided were evaluated. The propensity score bin bootstrap (PSBB) approach was used to validate base-case results.
At mean follow-up of 2.7 years, CABG compared with PCI was associated with increased costs and greater all-cause mortality, but a significantly lower rate of MACCE. An ICER of $55,255 (Australian dollars)/MACCE avoided was observed for the overall cohort. The ICER varied across comparisons against bare metal stents (ICER $25,815/MACCE avoided), all drug-eluting stents (DES) ($56,861), second-generation DES ($42,925), and third-generation of DES ($88,535). Moderate-to-low ICERs were apparent for high-risk subgroups, including those with chronic kidney disease ($62,299), diabetes ($42,819), history of myocardial infarction ($30,431), left main coronary artery disease ($38,864), and heart failure ($36,966).
At early follow-up, high-risk subgroups had lower ICERs than the overall cohort when CABG was compared with PCI. A personalised, multidisciplinary approach to treatment of patients may enhance cost containment, as well as improving clinical outcomes following revascularisation strategies.
The authors sincerely acknowledge Jason Bryer, Ph.D., Executive Director at Excelsior College, Albany, NY, for writing a program for the propensity score bin bootstrap (PSBB) method in R, for the purpose of this project. The authors sincerely thank Mr. Marco Luthe, former Information Manager—Clinical Costing, at the Alfred Hospital Clinical Performance Unit, for his support with gathering clinical costing data, its interpretation, and performing the record linkage. The following investigators, data managers and institutions participated in the MIG database: The Alfred Hospital: S. J. Duffy, J. A. Shaw, A. Walton, A. Dart, A. Broughton, J. Federman, C. Keighley, C. Hengel, K. H. Peter, D. Stub, W. Chan, S. Nanayakkara, J. O’Brien, L. Selkrig, K. Rankin, R. Huntington, S. Pally; Austin Hospital: D. J. Clark, O. Farouque, M. Horrigan, J. Johns, L. Oliver, J. Brennan, R. Chan, G. Proimos, T. Dortimer, B. Chan, R. Huq, D. Fernando, M. Yudi, K. Charter, L. Brown, A. AlFiadh, J. Ramchand, S. Picardo; Ballarat Base Hospital: E. Oqueli, A. Sharma, C. Hengel, N. Ryan, T. Harrison, C. Barry; Box Hill Hospital: M. Freeman, L. Roberts, A. Teh, M. Rowe, G. Proimos, Y. Cheong, C. Goods, D. Fernando, J. Ramzy, A. Kosky, P. Venkataraman; Monash University: C. Reid, N. Andrianopoulos, A. L. Brennan, D. Dinh, B. P. Yan; Royal Melbourne Hospital: A. E. Ajani, R. Warren, D. Eccleston, J. Lefkovits, R. Iyer, R. Gurvitch, W. Wilson, M. Brooks, S. Biswas, J. Yeoh; University Hospital, Geelong: C. Hiew, M. Sebastian, T. Yip, M. Mok, C. Jaworski, A. Hutchison, M. Turner, B. Khialani, B. McDonald, R. Pavletich. The following investigators, data managers, and institutions participated in the ANZSCTS database: The Alfred Hospital: McGiffin D, Kaczmarek M; Austin Hospital: Matalanis G, Shaw M; Cabrini Health: Rowland M, Shardey G; Epworth HeathCare: Skillington P, Almeida A, Chorley T, Baker L; Geelong Hospital: Seevanayagam S, Bright C; Flinders Medical Centre: Baker R, Edmonds C; Fiona Stanley Hospital: Larbalestier R, Kruger R; Holy Spirit Northside: Fayers T, Kyte, M, Doran C; Jessie McPherson Private Hospital: Smith J, White H; John Hunter Hospital: Seah P, Scaybrook S; Lake Macquarie Hospital: James A, Goodwin K; Liverpool Hospital: French B, Hewitt N; Mater Health Services: Lopez G, Curtis L; Monash Medical Centre: Smith J, White H; Peninsula Private Hospital: Tiruvoipati R, Norton N; Prince of Wales Hospital: Wolfenden H, Muir V; Queensland Health: Milne J; Royal Adelaide Hospital: Worthington M, Wong C; Royal Melbourne Hospital: Tatoulis J, Wynne R; Royal North Shore Hospital: Marshman D, Jovanovic-Palic D; Royal Prince Alfred Hospital: Bannon P, Turner L; Sir Charles Gairdner Hospital: Passage J, Kolybaba M; St George Hospital: Fermanis G, Newbon P; St John of God Hospital: Passage J, Kolybaba M; St Vincent’s Hospital, VIC: Newcomb A, Mack J, Duve K; St Vincent’s Hospital, NSW: Spratt P, Hunter T; The Canberra Hospital: Bissaker P, Dennis N, Burke N; Westmead Hospital: Chard R, Halaka M; Monash CCRE Therapeutics: Tran L, Nag N, Reid CM.
Compliance with Ethical Standards
TVA was supported by the National Heart Foundation of Australia Postgraduate Research Scholarship (PC 10M 5457). SJD’s and CMR’s work is supported by National Health and Medical Research Council of Australia grants. The MIG acknowledges funding from Abbott Vascular, Astra-Zeneca, Medtronic, MSD, Pfizer, Servier, and The Medicines Company. These companies do not have access to data and do not have the right to review manuscripts or abstracts before publication. The Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) National Cardiac Surgery Database Program is funded by the Department of Health and Human Services, Victoria, the Health Administration Corporation (GMCT) and the Clinical Excellence Commission (CEC), NSW, and funding from individual units. ANZSCTS research activities are supported through a National Health and Medical Research Council Senior Research Fellowship and Program Grant awarded to C. M. Reid.
This record linkage study, undertaken as part of this evaluation at The Alfred Hospital, was approved on 24 March 2015 by The Alfred Hospital’s Ethics Committee in the category of a ‘low risk review’ (Project number 142/15).
Conflict of interest
All authors (TVA, ZA, MH, FR, SJD, BP, CHY, JS, BB, BPY, ALB, LT, and CMR) declare no competing interests and take responsibility for all aspects of the data presented (including reliability and freedom from bias) and their discussed interpretation. The authors report no relationships that could be construed as a conflict of interest.
Data availability statement
The datasets generated and analysed during the current study are not publicly available as they contain sensitive patient and hospital-specific information. They may be available in the de-identified form from the corresponding author on reasonable request.
- 4.Kirtane AJ, Gupta A, Iyengar S, et al. Safety and efficacy of drug-eluting and bare metal stents. Compr Meta Anal Random Trials Obs Stud. 2009;119:3198–206.Google Scholar
- 5.Yan BP, Clark DJ, Buxton B, et al. Clinical characteristics and early mortality of patients undergoing coronary artery bypass grafting compared to percutaneous coronary intervention: Insights from the Australasian Society of Cardiac and Thoracic Surgeons (ASCTS) and the Melbourne Interventional Group (MIG) Registries. Heart Lung Circ. 2009;18:184–90.CrossRefPubMedGoogle Scholar
- 8.Kapur A, Hall RJ, Malik IS, et al. Randomized comparison of percutaneous coronary intervention with coronary artery bypass grafting in diabetic patients: 1-year results of the CARDia (Coronary Artery Revascularization in Diabetes) trial. J Am Coll Cardiol. 2010;55:432–40.CrossRefPubMedGoogle Scholar
- 10.Cohen DJ, Osnabrugge RL, Magnuson EA, et al. Cost-effectiveness of percutaneous coronary intervention with drug-eluting stents vs. bypass surgery for patients with 3-vessel or left main coronary artery disease: final results from the SYNTAX trial. Circulation. 2014;130:1146–57.CrossRefPubMedGoogle Scholar
- 11.Magnuson EA, Farkouh ME, Fuster V, et al. Cost-effectiveness of percutaneous coronary intervention with drug eluting stents versus bypass surgery for patients with diabetes and multivessel coronary artery disease: results from the FREEDOM trial. Circulation. 2012;127:820–31.CrossRefPubMedPubMedCentralGoogle Scholar
- 21.Domínguez-Franco AJ, Jiménez-Navarro MF, Hernández-García JM, et al. Comparison of medium-term outcomes obtained with drug-eluting stents and coronary artery bypass grafts in an unselected population of diabetic patients with multivessel coronary disease. Propensity score analysis. Revista Española de Cardiología (English Edition). 2009;62:491–500.CrossRefGoogle Scholar
- 26.Klein LW, Edwards FH, DeLong ER, Ritzenthaler L, Dangas GD, Weintraub WS. ASCERT: the American College of Cardiology Foundation—the Society of Thoracic Surgeons Collaboration on the comparative effectiveness of revascularization strategies. JACC Cardiovasc Interv. 2010;3:124–6.CrossRefPubMedGoogle Scholar
- 29.Stuart EA. Matching methods for causal inference: a review and a look forward. Stat Sci Rev J Inst Math Stat. 2010;25:1.Google Scholar
- 31.Faries DE, Peng X, Obenchain RL. Costs and cost effectiveness analysis using propensity score bin bootstrapping. In: Faries DE, Leon AC, Haro JM, Obenchain RL, editors. Analysis of Observational Health Care Data Using SAS. Cary, NC: SAS Institute; 2010.Google Scholar
- 33.Australian Government Medical Services Advisory Committee 2017. MSAC Applications Page. http://www.msac.gov.au/internet/msac/publishing.nsf/Content/application-page. Accessed 23 Mar 2017.
- 34.Australian Institute of Health and Welfare 2016. Health expenditure Australia 2014–15. Health and welfare expenditure series no. 57. Cat. no. HWE 67. Canberra: AIHW.Google Scholar
- 35.Medicare Benefits Scedule (MBS) Online. http://www.mbsonline.gov.au/internet/mbsonline/publishing.nsf/Content/Home. Accessed 4 Jan 2017.
- 37.Perikhanyan A. Effectiveness and cost-effectiveness of coronary artery bypass surgery versus drug eluting stents in Armenia: a feasibility study. Georgian Med News. 2011;6:44–51.Google Scholar
- 45.Australian Commission on Safety and Quality in Health Care 2015, National core, hospital based outcome indicator specification, ACSQHC, Sydney. https://vwwv.safetyandguality.gov.au/wp-content/uploads/2015/06/National-core-hospital-based-outcome-indicators-consultation.pdf. Accessed 4 Dec 2016.